An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease

JaeHee Cheon, Won Ho Kim

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Purpose of review This review discusses recent scientific developments in the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Recent findings Gastrointestinal involvement is a major cause of morbidity and mortality in Behçet's disease. Patient clinical data are scarce because of the rarity of the disease; however, novel diagnostic criteria and disease activity indices have been developed recently to aid treatment of Behçet's disease patients. Current therapies include 5-aminosalicylic acids, corticosteroids, immunomodulators, or antitumor necrosis factor alpha agents. Antitumor necrosis factor alpha agents can achieve clinical responses and remission in patients that were previously nonresponsive to corticosteroids or immunomodulators. Clinical variables, including young age and higher disease activity at the time of diagnosis, volcano-type ulcers, absence of mucosal healing, higher C-reactive protein levels, prior history of surgery, and lack of initial response to medical therapy, can be regarded as poor prognostic factors. Summary Previously, the diagnosis and management of intestinal Behçet's disease depended upon the expertise of individual clinicians; however, more standardized medical assessments and improved treatment regimens for Behçet's disease patients are evolving.

Original languageEnglish
Pages (from-to)24-31
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume27
Issue number1
DOIs
Publication statusPublished - 2015 Jan 11

Fingerprint

Intestinal Diseases
Immunologic Factors
Adrenal Cortex Hormones
Necrosis
Therapeutics
Mesalamine
C-Reactive Protein
Ulcer
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

@article{6567ae8bc9b24c208eb3bae6b9a92d44,
title = "An update on the diagnosis, treatment, and prognosis of intestinal Beh{\cc}et's disease",
abstract = "Purpose of review This review discusses recent scientific developments in the diagnosis, treatment, and prognosis of intestinal Beh{\cc}et's disease. Recent findings Gastrointestinal involvement is a major cause of morbidity and mortality in Beh{\cc}et's disease. Patient clinical data are scarce because of the rarity of the disease; however, novel diagnostic criteria and disease activity indices have been developed recently to aid treatment of Beh{\cc}et's disease patients. Current therapies include 5-aminosalicylic acids, corticosteroids, immunomodulators, or antitumor necrosis factor alpha agents. Antitumor necrosis factor alpha agents can achieve clinical responses and remission in patients that were previously nonresponsive to corticosteroids or immunomodulators. Clinical variables, including young age and higher disease activity at the time of diagnosis, volcano-type ulcers, absence of mucosal healing, higher C-reactive protein levels, prior history of surgery, and lack of initial response to medical therapy, can be regarded as poor prognostic factors. Summary Previously, the diagnosis and management of intestinal Beh{\cc}et's disease depended upon the expertise of individual clinicians; however, more standardized medical assessments and improved treatment regimens for Beh{\cc}et's disease patients are evolving.",
author = "JaeHee Cheon and Kim, {Won Ho}",
year = "2015",
month = "1",
day = "11",
doi = "10.1097/BOR.0000000000000125",
language = "English",
volume = "27",
pages = "24--31",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. / Cheon, JaeHee; Kim, Won Ho.

In: Current Opinion in Rheumatology, Vol. 27, No. 1, 11.01.2015, p. 24-31.

Research output: Contribution to journalReview article

TY - JOUR

T1 - An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease

AU - Cheon, JaeHee

AU - Kim, Won Ho

PY - 2015/1/11

Y1 - 2015/1/11

N2 - Purpose of review This review discusses recent scientific developments in the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Recent findings Gastrointestinal involvement is a major cause of morbidity and mortality in Behçet's disease. Patient clinical data are scarce because of the rarity of the disease; however, novel diagnostic criteria and disease activity indices have been developed recently to aid treatment of Behçet's disease patients. Current therapies include 5-aminosalicylic acids, corticosteroids, immunomodulators, or antitumor necrosis factor alpha agents. Antitumor necrosis factor alpha agents can achieve clinical responses and remission in patients that were previously nonresponsive to corticosteroids or immunomodulators. Clinical variables, including young age and higher disease activity at the time of diagnosis, volcano-type ulcers, absence of mucosal healing, higher C-reactive protein levels, prior history of surgery, and lack of initial response to medical therapy, can be regarded as poor prognostic factors. Summary Previously, the diagnosis and management of intestinal Behçet's disease depended upon the expertise of individual clinicians; however, more standardized medical assessments and improved treatment regimens for Behçet's disease patients are evolving.

AB - Purpose of review This review discusses recent scientific developments in the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Recent findings Gastrointestinal involvement is a major cause of morbidity and mortality in Behçet's disease. Patient clinical data are scarce because of the rarity of the disease; however, novel diagnostic criteria and disease activity indices have been developed recently to aid treatment of Behçet's disease patients. Current therapies include 5-aminosalicylic acids, corticosteroids, immunomodulators, or antitumor necrosis factor alpha agents. Antitumor necrosis factor alpha agents can achieve clinical responses and remission in patients that were previously nonresponsive to corticosteroids or immunomodulators. Clinical variables, including young age and higher disease activity at the time of diagnosis, volcano-type ulcers, absence of mucosal healing, higher C-reactive protein levels, prior history of surgery, and lack of initial response to medical therapy, can be regarded as poor prognostic factors. Summary Previously, the diagnosis and management of intestinal Behçet's disease depended upon the expertise of individual clinicians; however, more standardized medical assessments and improved treatment regimens for Behçet's disease patients are evolving.

UR - http://www.scopus.com/inward/record.url?scp=84918593777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918593777&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000125

DO - 10.1097/BOR.0000000000000125

M3 - Review article

C2 - 25405821

AN - SCOPUS:84918593777

VL - 27

SP - 24

EP - 31

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 1

ER -